Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1959 1
2007 2
2009 1
2010 2
2011 2
2012 3
2013 6
2015 1
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma.
Salles G, Schuster SJ, Dreyling M, Fischer L, Kuruvilla J, Patten PEM, von Tresckow B, Smith SM, Jiménez-Ubieto A, Davis KL, Anjos C, Chu J, Zhang J, Lobetti Bodoni C, Thieblemont C, Fowler NH, Dickinson M, Martínez-López J, Wang Y, Link BK. Salles G, et al. Among authors: lobetti bodoni c. Blood Adv. 2022 Nov 22;6(22):5835-5843. doi: 10.1182/bloodadvances.2022008150. Blood Adv. 2022. PMID: 35973192 Free PMC article. Clinical Trial.
Telomeres and telomerase in normal and malignant B-cells.
Lobetti-Bodoni C, Bernocco E, Genuardi E, Boccadoro M, Ladetto M. Lobetti-Bodoni C, et al. Hematol Oncol. 2010 Dec;28(4):157-67. doi: 10.1002/hon.937. Hematol Oncol. 2010. PMID: 20213664 Review.
Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma.
Jaeger U, Tam CS, Borchmann P, McGuirk JP, Johansen M, Waller EK, Jaglowski S, Andreadis C, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Salles G, Schuster SJ, He F, Maziarz RT, Mayer S, Makita S, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Goto H, Colicino S, Agarwal A, Lobetti-Bodoni C, Bishop MR. Jaeger U, et al. Among authors: lobetti bodoni c. Blood Adv. 2022 Aug 23;6(16):4816-4820. doi: 10.1182/bloodadvances.2021006193. Blood Adv. 2022. PMID: 35687492 Free PMC article. No abstract available.
Life expectancy of young adults with follicular lymphoma.
Conconi A, Lobetti-Bodoni C, Montoto S, Lopez-Guillermo A, Coutinho R, Matthews J, Franceschetti S, Bertoni F, Moccia A, Rancoita PM, Gribben J, Cavalli F, Gaidano G, Lister TA, Montserrat E, Ghielmini M, Zucca E. Conconi A, et al. Among authors: lobetti bodoni c. Ann Oncol. 2015 Nov;26(11):2317-22. doi: 10.1093/annonc/mdv376. Epub 2015 Sep 11. Ann Oncol. 2015. PMID: 26362567 Free article.
Hepatitis C virus and GBV-C virus prevalence among patients with B-cell lymphoma in different European regions: a case-control study of the International Extranodal Lymphoma Study Group.
Nicolosi Guidicelli S, Lopez-Guillermo A, Falcone U, Conconi A, Christinat A, Rodriguez-Abreu D, Grisanti S, Lobetti-Bodoni C, Piffaretti JC, Johnson PW, Mombelli G, Cerny A, Montserrat E, Cavalli F, Zucca E. Nicolosi Guidicelli S, et al. Among authors: lobetti bodoni c. Hematol Oncol. 2012 Sep;30(3):137-42. doi: 10.1002/hon.1015. Epub 2011 Nov 21. Hematol Oncol. 2012. PMID: 22105737
Risk factors of central nervous system relapse in mantle cell lymphoma.
Conconi A, Franceschetti S, Lobetti-Bodoni C, Stathis A, Margiotta-Casaluci G, Ramponi A, Mazzucchelli L, Bertoni F, Ghielmini M, Gaidano G, Cavalli F, Zucca E. Conconi A, et al. Among authors: lobetti bodoni c. Leuk Lymphoma. 2013 Sep;54(9):1908-14. doi: 10.3109/10428194.2013.767454. Epub 2013 Feb 20. Leuk Lymphoma. 2013. PMID: 23339449
Incidence, risk factors and outcome of histological transformation in follicular lymphoma.
Conconi A, Ponzio C, Lobetti-Bodoni C, Motta M, Rancoita PM, Stathis A, Moccia AA, Mazzucchelli L, Bertoni F, Ghielmini M, Cavalli F, Zucca E. Conconi A, et al. Among authors: lobetti bodoni c. Br J Haematol. 2012 Apr;157(2):188-96. doi: 10.1111/j.1365-2141.2012.09054.x. Epub 2012 Feb 20. Br J Haematol. 2012. PMID: 22348437 Free article.
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program.
Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, Chiappella A, Baldini L, Rossi G, Pulsoni A, Di Raimondo F, Rigacci L, Pinto A, Galimberti S, Bari A, Rota-Scalabrini D, Ferrari A, Zaja F, Gallamini A, Specchia G, Musto P, Rossi FG, Gamba E, Evangelista A, Vitolo U; Fondazione Italiana Linfomi. Ladetto M, et al. Among authors: lobetti bodoni c. Blood. 2013 Nov 28;122(23):3759-66. doi: 10.1182/blood-2013-06-507319. Epub 2013 Oct 1. Blood. 2013. PMID: 24085766 Free article. Clinical Trial.
19 results